/PHG
PHG Stock - Koninklijke Philips N.V.
Healthcare|Medical - DevicesNYSE
$26.66+0.64%
+$0.17 (+0.64%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.48
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $29.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PHG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.39 – $26.93
TARGET (TP)$30.66
STOP LOSS$24.53
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$29.54
52W Low$21.48
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18.02B | $18.17B | $17.83B | $17.16B | $17.31B |
| Gross Profit | $7.77B | $7.45B | $7.19B | $7.17B | $7.91B |
| Gross Margin | 43.1% | 41.0% | 40.4% | 41.8% | 45.7% |
| Operating Income | $529.00M | $-115,000,000 | $-1,529,000,000 | $553.00M | $1.26B |
| Net Income | $-702,000,000 | $-466,000,000 | $-1,608,000,000 | $3.32B | $1.19B |
| Net Margin | -3.9% | -2.6% | -9.0% | 19.3% | 6.9% |
| EPS | $-0.75 | $-0.49 | $-1.68 | $0.67 | $1.25 |
Company Overview
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
31%
Hold / Neutral
7
44%
Sell / Underperform
4
25%
Analyst Consensus🔴 Bearish
5 Bullish11 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | RBC Capital Mkts | Initiation | Sector Perform | - |
| February 25th 2025 | Exane BNP Paribas | Upgrade | Outperform | - |
| February 20th 2025 | UBS | Upgrade | Buy | - |
| October 29th 2024 | Jefferies | Upgrade | Hold | - |
| May 13th 2024 | Bernstein | Upgrade | Outperform | - |
| May 7th 2024 | Exane BNP Paribas | Upgrade | Neutral | - |
| April 30th 2024 | UBS | Upgrade | Neutral | - |
| April 30th 2024 | JP Morgan | Upgrade | Neutral | - |
| February 7th 2024 | Exane BNP Paribas | Downgrade | Underperform | - |
| July 12th 2023 | Goldman | Initiation | Buy | - |
| January 17th 2023 | UBS | Downgrade | Sell | - |
| October 18th 2022 | Morgan Stanley | Initiation | Equal Weight | - |
| October 14th 2022 | Deutsche Bank | Downgrade | Sell | - |
| September 12th 2022 | Societe Generale | Upgrade | Buy | - |
| September 6th 2022 | UBS | Upgrade | Neutral | - |
Earnings History & Surprises
PHGBeat Rate
60%
Last 15 quarters
Avg Surprise
+52.9%
EPS vs Estimate
Beats / Misses
9/4
2 met exactly
Latest EPS
$0.37
Q4 2025
EPS Surprise History
Q1 24
+7.3%
$0.44vs$0.41
Q2 24
+7.7%
$0.28vs$0.26
Q3 24
+28.0%
$0.32vs$0.25
Q4 24
0.0%
$0.35vs$0.35
Q1 25
-1.8%
$0.54vs$0.55
Q2 25
+92.9%
$0.27vs$0.14
Q3 25
+29.2%
$0.41vs$0.32
Q4 25
0.0%
$0.37vs$0.37
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.37 | $0.37 | 0.0% | = MET |
Q3 2025 | Jul 29, 2025 | $0.32 | $0.41 | +29.2% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.14 | $0.27 | +92.9% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $0.55 | $0.54 | -1.8% | ✗ MISS |
Q4 2024 | Oct 28, 2024 | $0.35 | $0.35 | 0.0% | = MET |
Q3 2024 | Jul 29, 2024 | $0.25 | $0.32 | +28.0% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $0.26 | $0.28 | +7.7% | ✓ BEAT |
Q1 2024 | Jan 29, 2024 | $0.41 | $0.44 | +7.3% | ✓ BEAT |
Q4 2023 | Oct 23, 2023 | $0.18 | $0.36 | +100.0% | ✓ BEAT |
Q3 2023 | Jul 24, 2023 | $0.23 | $0.31 | +34.8% | ✓ BEAT |
Q2 2023 | Apr 24, 2023 | $0.19 | $0.24 | +26.3% | ✓ BEAT |
Q1 2023 | Jan 30, 2023 | $0.06 | $0.42 | +600.0% | ✓ BEAT |
Q4 2022 | Oct 24, 2022 | — | $0.25 | — | — |
Q3 2022 | Jul 25, 2022 | $0.38 | $0.15 | -60.0% | ✗ MISS |
Q2 2022 | Apr 25, 2022 | — | $0.32 | — | — |
Q1 2022 | Jan 24, 2022 | $1.37 | $0.65 | -52.6% | ✗ MISS |
Q4 2021 | Oct 18, 2021 | $0.57 | $0.47 | -17.5% | ✗ MISS |
Q3 2021 | Jul 26, 2021 | — | $0.17 | — | — |
Latest News
Philips To Acquire SpectraWAVE, Expanding AI-Powered Coronary Imaging And Physiological Assessment Portfolio; Deal Terms Not Disclosed
📈 PositiveBenzinga•Dec 15, 2025, 07:06 AM
Reported Sunday, Philips Launches BlueSeal Horizon Industry's First Helium Free 3.0T MRI With AI Powered Clinical And Workflow Innovations
📈 PositiveBenzinga•Dec 1, 2025, 07:02 AM•Also:
Reported Sunday, Philips Introduces Verida Spectral CT With Full AI Integration Enabling Lower Dose Faster Reconstruction And High Precision Imaging
📈 PositiveBenzinga•Dec 1, 2025, 06:58 AM
Philips Reiterates Confidence In Full-Year 2025 Outlook With 1%-3% Comparable Sales Growth, Adjusted EBITA Margin Up To 11.8%, And EUR 0.2B–0.4B Free Cash Flow
📈 PositiveBenzinga•Nov 4, 2025, 06:53 AM
Koninklijke Philips Q3 Adj. EPS $0.42 Beats $0.37 Estimate, Sales $5.030B Inline
📈 PositiveBenzinga•Nov 4, 2025, 06:51 AM
Royal Philips Selected By Hoag To Upgrade Patient Monitoring Throughout Hoag's Hospitals Under 10-Year Partnership
📈 PositiveBenzinga•Oct 30, 2025, 12:12 PM
Philips Study Finds Treating All Blocked Arteries During First Heart Attack Procedure Is Safe and Effective
📈 PositiveBenzinga•Oct 29, 2025, 10:09 AM
Philips shares are trading lower after the FDA issued a warning letter following inspections of ultrasound facilities in the U.S. and the Netherlands.
📉 NegativeBenzinga•Oct 28, 2025, 03:02 PM
Philips On FDA Warning Letter, Says Takes It Very Seriously And Has Submitted Response In Accordance With Regulatory Requirements
➖ NeutralBenzinga•Oct 28, 2025, 02:53 PM
Reported Earlier: FDA Issues Warning Letter To Philips Ultrasound Following Inspections Of Facilities In Bothell, Washington And Reedsville, Pennsylvania, As Well As At Philips Medical Systems Nederland In The Netherlands Between January And March 2025
📉 NegativeBenzinga•Oct 28, 2025, 02:52 PM
Philips Celebrates 5,000th Zenition Mobile C-Arm Installation, Enhancing Surgical And Interventional Care In Over 170 Countries
📈 PositiveBenzinga•Oct 8, 2025, 08:10 AM
Reported Earlier: Royal Philips Signs Deal With Optum Healthcare To Offer Mobile Cardiac Telemetry, Extended Holter Services Through Optum's Network In US
📈 PositiveBenzinga•Sep 25, 2025, 03:00 PM
'Philips in talks with US over probes of medical technology imports' -Reuters
➖ NeutralBenzinga•Sep 25, 2025, 11:41 AM
Philips Intends To Extend 4M Share Incentive Settlement Under 2023 Buyback Plan To Q4 2026
📈 PositiveBenzinga•Sep 15, 2025, 10:39 AM
Philips Announces Intention To Extend Settlement Of Two Forward Contracts For 2M Shares Under Share Repurchase Program
➖ NeutralBenzinga•Sep 15, 2025, 08:39 AM
'Ventilator Recall: Philips Respironics Removes Certain DreamStation Devices Due to Programming Errors That Can Result in Failed Therapy Modes' - FDA
📉 NegativeBenzinga•Sep 12, 2025, 06:38 PM
Philips And Masimo Partner To Advance Access To Patient Monitoring Measurement Technologies
📈 PositiveBenzinga•Sep 11, 2025, 12:10 PM•Also:
Philips Philips Foundation And MedShare Launch Program To Strengthen US Healthcare Readiness For Natural Disasters With Forward Thinking Preparedness Model
📈 PositiveBenzinga•Sep 10, 2025, 11:21 AM
Reuters Cites Paris Prosecutors Saying Public Health Unit Has Received 104 Complaints About Philips' Recall Of Sleep Therapy Devices
📉 NegativeBenzinga•Sep 8, 2025, 02:04 PM
Philips Announces It Has Launched The Next-Generation Telemetry Monitor 5500, A New Telemetry Platform Aimed At Tackling Key Healthcare Challenges Such As Staff Shortages And Alarm Management
📈 PositiveBenzinga•Sep 4, 2025, 01:03 PM
Frequently Asked Questions about PHG
What is PHG's current stock price?
Koninklijke Philips N.V. (PHG) is currently trading at $26.66 per share. The stock has moved +0.64% today.
What is the analyst price target for PHG?
No analyst price targets are currently available for this stock.
What sector is Koninklijke Philips N.V. in?
Koninklijke Philips N.V. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is PHG's market cap?
Koninklijke Philips N.V. has a market capitalization of $25.35 billion, making it a large-cap company.
Does PHG pay dividends?
No, Koninklijke Philips N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBNTX
BioNTech SE
$92.50
Mkt Cap: $22.2B
DXCM
DexCom, Inc.
$66.06
Mkt Cap: $25.8B
LH
Labcorp Holdings Inc.
$252.03
Mkt Cap: $20.9B
MTD
Mettler-Toledo International Inc.
$1402.51
Mkt Cap: $28.7B
NTRA
Natera, Inc.
$231.96
Mkt Cap: $32.0B
PODD
Insulet Corporation
$289.62
Mkt Cap: $20.4B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
TEVA
Teva Pharmaceutical Industries Limited
$30.35
Mkt Cap: $34.8B
ZBH
Zimmer Biomet Holdings, Inc.
$89.13
Mkt Cap: $17.7B
Explore stocks similar to PHG for comparison